Formoterol in the management of chronic obstructive pulmonary disease

@article{Steiropoulos2008FormoterolIT,
  title={Formoterol in the management of chronic obstructive pulmonary disease},
  author={Paschalis Steiropoulos and Argyrios Tzouvelekis and Demosthenes E Bouros},
  journal={International Journal of Chronic Obstructive Pulmonary Disease},
  year={2008},
  volume={3},
  pages={205 - 216}
}
Bronchodilators represent the hallmark of symptomatic treatment of Chronic Obstructive Pulmonary Disease (COPD). There are four categories of bronchodilators: anticholinergics, methylxanthines, short-acting beta2-agonists, and long-acting beta2-agonists such as formoterol. Significant research has been performed to investigate the efficacy, safety and tolerability of formoterol in the therapeutic field of COPD. Formoterol exhibits a rapid onset of bronchodilation similar to that observed with… CONTINUE READING
20 Citations
59 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study

  • F Di Marco, M Verga, P Santus
  • Respir Med,
  • 2006
Highly Influential
4 Excerpts

The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease

  • Mahler DA.
  • J Allergy Clin Immunol, 110:S298–303.
  • 2002
Highly Influential
4 Excerpts

Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility

  • D Bouros, J Kottakis, V Le Gros
  • Curr Med Res Opin,
  • 2004
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…